- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03187405
Intraventricular Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage. (FIVHeMA)
Intraventricular Fibrinolysis Versus External Ventricular Drainage Alone in Aneurysmal Subarachnoid Hemorrhage: a Randomized Controlled Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Introduction: Aneurysmal subarachnoid hemorrhage (SAH) is a devastating form of stroke, which often causes acute hydrocephalus requiring the insertion of an external ventricular drain (EVD). A major complication of aneurysmal SAH is delayed cerebral ischemia (DCI), which corresponds to the occurrence of an ischemic stroke up to 21 days after the aneurysm rupture. There are currently only few ways to prevent it. As DCI is linked to the presence of blood within the subarachnoid space, it has been hypothesized that removing this blood may decrease the risk of DCI. It could be obtained by injecting a fibrinolytic agent through the EVD, a therapeutic strategy named intraventricular fibrinolysis (IVF). There are several evidences, both in preclinical and in clinical studies that IVF controls the phenomenon that are leading to DCI. It has notably been shown in Phase I and Phase II trial that IVF in aneurysmal SAH is safe and may decrease the risk of DCI, with a trend to improve the rate of good functional outcome by about 10%. Here, the investigators propose to conduct a phase III trial to provide a clear evaluation of the impact of IVF after aneurysmal SAH.
Materials and methods: this study will include patients with aneurysmal SAH requiring external ventricular drainage. The investigators will perform a pragmatic randomized controlled trial: compare the standard of care, i.e. the EVD alone, to the experimental treatment, i.e. IVF, with an open design. After exclusion of the aneurysm, patients will be randomly allocated to receive either EVD alone or EVD+IVF (72 hours, 9 doses). The primary outcome will be the proportion of patients without severe disability 6 months after the aneurysm rupture, as evaluated by the modified Rankin Scale (mRS). The investigators plan to include 440 patients, to show an increase of the rate of good functional outcome of 10% in the EVD+IVF group compared to the EVD alone group (α=0.05 and β=0.8). To obtain such sample, a multicenter trial is mandatory, and to date 16 centers accepted to participate. Each center will include one patient per month, and the inclusion period is to last 48 months.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Caen, France, F-14000
- University Hospital of Caen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients (age 18-75) with SAH on initial CT-Scan examination.
- SAH associated with hydrocephalus requiring external ventricular drainage.
- Confirmation of an associated intracranial aneurysm by vascular imaging.
- Time from onset to admission under 24 hours.
- Exclusion of the aneurysm by surgical clipping or endovascular coiling before IVF.
- Oral information on research and informed consent of the patient and/or his relatives.
Exclusion Criteria:
- Patient with severe clinical presentation on admission: WFNS score = 5.
- Associated intracerebral hematoma of more than 2 cm in its larger width.
- SAH diagnosed on lumbar puncture: original Fisher grade = 1.
- Impossibility to exclude the aneurysm within 72 hours following its rupture.
- Patient previously treated with antiplatelet therapy or treated with antiplatelet therapy after the aneurysm exclusion.
- Severe coagulopathy, including oral vitamin K antagonist.
- Pregnant or lactating woman.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: EVD alone
In the EVD alone group group, the EVD will be managed as usual - i.e. will only be used to drain CSF.
|
|
Experimental: EVD + IVF with Alteplase
Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
|
Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participants With Modified Rankin Scale (mRS) <=3 - Dichotomized Analysis.
Time Frame: 6 months.
|
Proportion of patients without severe disability evaluated by the modified Rankin Scale (0-3).
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.
It is scored from 0 (perfect health without symptoms) to 6 (death).
|
6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Death
Time Frame: 6 months
|
Risk of death
|
6 months
|
DCI.
Time Frame: 6 weeks
|
The presence of cerebral infarction on CT or MR scan on the latest CT or MR scan made before death within 6 weeks, not present on the CT or MR scan between 24 and 48 hours after early aneurysm occlusion, and not attributable to other causes such as surgical clipping or endovascular treatment.
|
6 weeks
|
Clinical deterioration caused by DCI.
Time Frame: 1 month
|
Occurrence of focal neurological impairment (such as hemiparesis, aphasia, apraxia, hemianopia, or neglect), or a decrease of at least 2 points on the Glasgow Coma Scale.
This should last for at least 1 hour, is not apparent immediately after aneurysm occlusion, and cannot be attributed to other causes by means of clinical assessment, CT or MRI scanning of the brain, and appropriate laboratory studies
|
1 month
|
EVD obstruction.
Time Frame: 1 month
|
Numbers of permanent catheter obstruction requiring the insertion of a new catheter.
|
1 month
|
Internal CSF shunt surgery.
Time Frame: 3 months
|
Rate of internal CSF shunt surgery.
|
3 months
|
Rebleeding.
Time Frame: 4 days
|
A new ICH identified on a CT-scan performed after IVF that was not present before IVF.
|
4 days
|
Catheter related infection.
Time Frame: 3 month
|
Clinical picture of infection associated with a positive CSF culture.
|
3 month
|
Rate of patients who returned to work.
Time Frame: 6 months
|
Proportion of patient who returned to their previous professional activity.
|
6 months
|
Quality of life evaluated by the MOS SF-36 scale
Time Frame: 6 months
|
MOS SF-36 scale
|
6 months
|
Asthenia.
Time Frame: 6 months
|
Asthenia scale of Pichot
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Thomas Gaberel, MD, PhD, University Hospital, Caen
Publications and helpful links
General Publications
- Etminan N, Beseoglu K, Eicker SO, Turowski B, Steiger HJ, Hanggi D. Prospective, randomized, open-label phase II trial on concomitant intraventricular fibrinolysis and low-frequency rotation after severe subarachnoid hemorrhage. Stroke. 2013 Aug;44(8):2162-8. doi: 10.1161/STROKEAHA.113.001790. Epub 2013 Jun 4.
- Goulay R, Flament J, Gauberti M, Naveau M, Pasquet N, Gakuba C, Emery E, Hantraye P, Vivien D, Aron-Badin R, Gaberel T. Subarachnoid Hemorrhage Severely Impairs Brain Parenchymal Cerebrospinal Fluid Circulation in Nonhuman Primate. Stroke. 2017 Aug;48(8):2301-2305. doi: 10.1161/STROKEAHA.117.017014. Epub 2017 May 19.
- Hanley DF, Lane K, McBee N, Ziai W, Tuhrim S, Lees KR, Dawson J, Gandhi D, Ullman N, Mould WA, Mayo SW, Mendelow AD, Gregson B, Butcher K, Vespa P, Wright DW, Kase CS, Carhuapoma JR, Keyl PM, Diener-West M, Muschelli J, Betz JF, Thompson CB, Sugar EA, Yenokyan G, Janis S, John S, Harnof S, Lopez GA, Aldrich EF, Harrigan MR, Ansari S, Jallo J, Caron JL, LeDoux D, Adeoye O, Zuccarello M, Adams HP Jr, Rosenblum M, Thompson RE, Awad IA; CLEAR III Investigators. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet. 2017 Feb 11;389(10069):603-611. doi: 10.1016/S0140-6736(16)32410-2. Epub 2017 Jan 10.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Intracranial Hemorrhages
- Hemorrhage
- Subarachnoid Hemorrhage
- Molecular Mechanisms of Pharmacological Action
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Tissue Plasminogen Activator
Other Study ID Numbers
- FIVHeMA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Subarachnoid Hemorrhage
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingSubarachnoid Hemorrhage, Aneurysmal | Subarachnoid Hemorrhage, SpontaneousItaly
-
IRCCS San RaffaeleFondazione Policlinico Universitario Agostino Gemelli IRCCS; Azienda Ospedaliera... and other collaboratorsRecruitingSubarachnoid Hemorrhage, Aneurysmal | Poor Grade Subarachnoid HemorrhageItaly
-
Medical University InnsbruckRecruitingSubarachnoid Hemorrhage | Subarachnoid Hemorrhage, Aneurysmal | Aneurysmal Subarachnoid Hemorrhage | Vasospasm, CerebralAustria
-
Assiut UniversityNot yet recruitingPost-Traumatic Subarachnoid Hemorrhage
-
Methodist Health SystemRecruitingTraumatic Intracranial Subarachnoid HemorrhageUnited States
-
University of CalgaryUnknownIntraventricular Hemorrhage | Aneurysmal Subarachnoid HemorrhageCanada
-
Macmillan Research Group UKCenter for Applied Research & Education; SMS Medical College and HospitalCompletedTraumatic Subarachnoid Haemorrhage
-
University of Texas Southwestern Medical CenterRecruitingSubarachnoid Hemorrhage, AneurysmalUnited States
-
Milton S. Hershey Medical CenterRecruiting
-
Second Affiliated Hospital, School of Medicine,...RecruitingSubarachnoid Hemorrhage, AneurysmalChina
Clinical Trials on EVD + IVF with Alteplase
-
Ohio State UniversityIRRASRecruitingSubarachnoid Hemorrhage | Intraventricular Hemorrhage | Ventriculitis | Subdural HematomaUnited States
-
Instituto Valenciano de Infertilidad, IVI VALENCIACompleted
-
University of Southern CaliforniaConvaTec Inc.Recruiting
-
ART Fertility Clinics LLCCompleted
-
Institut Universitari DexeusTerminatedPolycystic Ovary Syndrome | In Vitro FertilizationSpain
-
Centre Hospitalier Sud FrancilienCompletedAcute Ischemic Stroke Due to Medium-vessel-occlusionFrance
-
Hadassah Medical OrganizationUnknown
-
Clinique OvoActive, not recruiting
-
Centre Hospitalier Sud FrancilienCompletedAcute Anterior Choroidal Infarction (ACI) | Paramedian Pontine Infarction (IPP)France
-
University of Cape TownPopulation Health Research Institute; Walter Sisulu UniversityUnknownPericardial EffusionSouth Africa